Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Virulence · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Gustavo G PerezInstitute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-5874-7348
Emanuelle V de LimaInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0001-5904-8816
Leticia S AntonioSchool of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-4843-8840
Eduardo Matheus M VidalInstitute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0009-0008-9488-0681
Raissa R ChristoffInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-7052-2643
Milla B PaivaExperimental Health Medicine Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.ORCID 0000-0003-0475-0768
Antônio José S GonçalvesInterdisciplinary Laboratory of Medical Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.ORCID 0000-0001-7868-8317
Marcia P OliveiraInterdisciplinary Laboratory of Medical Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
Maria BellioInstitute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-3360-2740
Robson Coutinho SilvaInstitute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-7318-0204
Robson da CostaSchool of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-1675-4742
Rodrigo T FigueiredoDuque de Caxias Campus, Federal University of Rio de Janeiro, Duque de Caxias, Brazil.ORCID 0000-0002-7551-8782
Julia R ClarkeInstitute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-6777-2051
Herbert L de Matos GuedesInstitute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0002-3819-3069
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Leishmaniasis is a group of neglected diseases that cause significant mortality and disability. In Brazil, the most prevalent form is cutaneous leishmaniasis, which is characterized by painless lesions despite intense inflammation and ulceration. While BALB/c mouse models exhibit hypersensitivity to inflammatory stimuli, C57BL/6 mice better mimic human-like lesion progression and nociception. This study aimed to investigate the mechanisms underlying nociception in cutaneous leishmaniasis using the C57BL/6 model. Following infection with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.